Published in J Immunother on May 15, 2006
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials (2012) 1.72
High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res (2009) 1.39
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res (2011) 1.33
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer (2008) 1.29
CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog (2011) 1.26
Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res (2008) 1.26
STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res (2014) 1.24
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res (2016) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res (2009) 1.13
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer (2009) 1.12
Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta (2007) 1.05
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res (2008) 1.03
In silico models of cancer. Wiley Interdiscip Rev Syst Biol Med (2010) 1.01
Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol (2012) 0.97
Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology (2013) 0.93
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res (2015) 0.91
Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Leukemia (2012) 0.91
In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment. Front Immunol (2011) 0.90
Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med (2013) 0.90
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol (2007) 0.87
Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci (2011) 0.86
The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Onco Targets Ther (2014) 0.86
The importance of the age factor in cancer vaccination at older age. Cancer Immunol Immunother (2009) 0.86
Gene expression signature for spontaneous cancer regression in melanoma pigs. Neoplasia (2008) 0.86
Surgery and sentinel lymph node biopsy. Semin Oncol (2007) 0.85
Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm (2012) 0.83
Aging and cancer vaccines. Crit Rev Oncog (2013) 0.82
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease. PLoS One (2013) 0.82
Cancer vaccines in old age. Exp Gerontol (2007) 0.81
Anti-α-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget (2015) 0.81
Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol (2008) 0.81
B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice. J Virol (2007) 0.81
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 0.80
Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology (2013) 0.80
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. Br J Cancer (2014) 0.80
4T1 Murine Mammary Carcinoma Cells Enhance Macrophage-Mediated Innate Inflammatory Responses. PLoS One (2015) 0.79
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. J Immunother (2016) 0.79
CD4(+)FOXP3(+) T regulatory cells decrease and CD3(+)CD8(+) T cells recruitment in TILs from melanoma metastases after electrochemotherapy. Clin Exp Metastasis (2016) 0.79
PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival. J Cancer Ther (2013) 0.79
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer. Transl Oncol (2012) 0.78
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. J Transl Med (2010) 0.78
Is cancer vaccination feasible at older age? Exp Gerontol (2014) 0.77
Adaptive Immune Responses and HER2/neu Positive Breast Cancer. Curr Pathobiol Rep (2013) 0.77
Spatial and functional heterogeneities shape collective behavior of tumor-immune networks. PLoS Comput Biol (2015) 0.77
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res (2017) 0.77
A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget (2016) 0.77
Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy. Cancers (Basel) (2011) 0.77
Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med (2013) 0.76
Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response. MAbs (2014) 0.76
Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep (2017) 0.75
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol (2003) 1.72
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother (2006) 1.57
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol (2006) 1.20
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol (2004) 0.94
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours. World J Surg Oncol (2004) 0.88
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol (2003) 0.85
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs (2006) 0.81
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS Lett (2005) 0.78
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate (2009) 0.76
Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol (2009) 0.75